Search the Newsreel

Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Trading Systems Reacting to (EOLS) Volatility

This article analyzes Evolus Inc. (NASDAQ: EOLS) using AI models to generate trading strategies. It highlights strong near and mid-term sentiment but a weak long-term outlook, identifying compelling upside potential as no resistance levels remain above the current price. The analysis provides specific entry, …

Evolus Inc (EOLS) Stock News Today

This page provides an overview of Evolus Inc (EOLS) stock news, earnings, analyst ratings, and key developments. It notes the current stock price, market cap, and indicates that more news will be coming soon. The page serves as a hub for investors to track …

Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen

Wall Street Zen has upgraded Evolus (NASDAQ:EOLS) from a "hold" to a "buy" rating, contributing to a "Moderate Buy" consensus among analysts with an average price target of $14.50. Shares of Evolus opened at $7.59, a 2.4% increase, and are nearing their 12-month high. …

Evolus, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EOLS) 2026-08-06

This article announces that Evolus, Inc. (EOLS) published its Q2 2026 earnings call presentation on August 6, 2026. The company reported Q2 EPS of -$0.02, beating estimates by $0.02, and revenue of $84.08 million, a 21.18% year-over-year increase, beating estimates by $2.54 million. The …

Evolus (EOLS) Stock Jumps On Margin Turn And EBITDA Momentum

Evolus Inc. Earnings Call Signals Confident Growth

Evolus, Inc. reported strong Q2 earnings with double-digit revenue growth and a third consecutive quarter of positive adjusted EBITDA, driven by its toxin franchise and growing international presence. Despite increased operating expenses and tariff uncertainty, the company raised its 2026 revenue guidance and reaffirmed …

Evolus Inc (EOLS) News, Articles, Events & Latest Updates

This article provides a compilation of recent news, articles, and updates concerning Evolus Inc (EOLS). Key highlights include Evolus reporting strong Q2 2026 financial results with positive adjusted EBITDA, expanding partnerships, and announcing future earnings report dates. The company also reported inducement grants of …

Evolus, Inc. Q2 2026: Revenue $84.08M, EPS ($0.12) — 10-Q Summary

Evolus, Inc. reported its Q2 2026 financial results, with revenue increasing to $84.08 million from $69.39 million in the prior year quarter, marking a 21.2% year-over-year growth. The company also narrowed its net loss, reporting a diluted EPS of ($0.12) compared to ($0.27) a …

Evolus targets $450M-$500M revenue and 13%-15% adjusted EBITDA margin in 2028 while raising 2026 revenue outlook to $330M-$337M

Earnings Call Insights: Evolus (EOLS) Q2 2026 MANAGEMENT VIEW * "The second quarter represents a meaningful inflection point for Evolus." (President, CEO & Director David Moatazedi) * "We delivered 21% revenue growth, generated our third consecutive quarter of positive adjusted EBITDA, expanded our international …

Earnings call transcript: Evolus tops revenue forecast in Q2 2026, shares rise

Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2

Evolus, Inc. (EOLS) reported break-even quarterly earnings per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $0.01 loss and significantly improving from a $0.24 loss a year ago. The company also exceeded revenue expectations, posting $84.08 million against an estimated $82.02 …

Evolus Q2 2026 slides: profitability streak continues, guidance raised

Evolus Inc. reported strong Q2 2026 results, with revenue up 21% year-over-year to $84.1 million, marking its third consecutive quarter of positive adjusted EBITDA. The company raised its full-year 2026 revenue guidance to $330-$337 million and reaffirmed its long-term target of $450-$500 million by …

Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses

Evolus (EOLS) reported strong Q2 2026 earnings, with revenue reaching $84.1 million, a 21.2% increase year-over-year, and slightly exceeding analyst estimates. The company also improved its financial performance by narrowing its operating and net losses. Insider trading activity showed sales by executives, while institutional …

Evolus (Nasdaq: EOLS) posts higher sales and manages sizable debt load

Evolus (NASDAQ: EOLS) lifts 2026 guidance after Q2 revenue hits $84.1 million

Evolus (NASDAQ: EOLS) reported strong Q2 2026 financial results with net revenue of $84.1 million, a 21% increase year-over-year, and positive adjusted EBITDA of $4.7 million. This marks the third consecutive quarter of positive adjusted EBITDA for the company. Consequently, Evolus has raised its …

Evolus Q2 Earnings Call Highlights

Evolus Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Evolus, Inc. (NASDAQ: EOLS) and reminds investors of the December 15, 2020 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Evolus made false and misleading …

Evolus, Inc. (NASDAQ: EOLS) extends Estyme deal to $500M markets

Evolus, Inc. has expanded its licensing agreement with Symatese Aesthetics to include exclusive commercialization rights for the Estyme® injectable hyaluronic acid gels in Canada, Australia, and New Zealand. This expansion, costing Evolus an upfront payment of €920,000 and potential regulatory milestone payments of up …

Evolus expands hyaluronic acid gel rights to three markets

Evolus Inc. has expanded its licensing and distribution agreement with Symatese to gain exclusive rights for commercializing Estyme injectable hyaluronic acid gels in Canada, Australia, and New Zealand. This move adds three new markets to Evolus's hyaluronic acid gel portfolio, with commercialization expected by …

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Evolus, Inc. has expanded its partnership with Symatese to gain exclusive rights to commercialize the Estyme® collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zealand. This expansion will complement Evolus' existing neurotoxin offerings (Jeuveau® and Nuceiva®) in these markets, creating …

Evolus Number of Employees 2026 | Employee Count & Headcount Data

Evolus, Inc. (EOLS) had approximately 348 employees worldwide as of March 2026, marking a 50.4% growth since 2023 but a 4.0% decline year-over-year in 2026. The company is actively hiring, with 53 job postings in 2026, and its workforce is predominantly located in the …

Evolus Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed profile of Evolus, Inc. (EOLS), a performance beauty company specializing in cash-pay aesthetic medical products. It outlines the company's key products, Jeuveau and Evolysse, and includes essential corporate information such as its CEO, IPO date, employee count, and contact …

Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis

The financial score for Evolus Inc (EOLS) is 8.00, placing it 82nd out of 155 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company reported a 6.74% year-over-year increase in its latest quarterly revenue to $73.14M and a …

Evolus Shareholder Alert

Faruqi & Faruqi, LLP, a securities law firm, is investigating potential claims against Evolus, Inc. following a federal securities class action lawsuit. The lawsuit alleges that Evolus made false statements regarding the origin of its Jeuveau™ product and misappropriated trade secrets from Medytox. This …

How Evolus Inc. (EOLS) Affects Rotational Strategy Timing

This article analyzes Evolus Inc. (EOLS) utilizing AI models to provide insights for a rotational strategy. It highlights a near-term strong sentiment challenging persistent mid and long-term weakness and identifies a significant risk-reward setup. The analysis offers three distinct institutional trading strategies—Position, Momentum Breakout, …

Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Evolus Inc (EOLS), detailing its price movement, support and resistance levels, and insights from various technical indicators and moving averages. The stock currently has a price momentum score of 4.73 and is trading between a resistance of …

Evolus Inc (EOLS) Institutional Confidence

The article provides an overview of Evolus Inc's institutional confidence, detailing its current score, industry ranking, and institutional shareholding proportion, which has decreased by 14.84% quarter-over-quarter. It lists key institutional shareholders and their recent activity. The institutional shareholding score for EOLS is 7.00, placing …

Evolus (EOLS) Projected to Post Quarterly Earnings on Wednesday

Evolus Market Sentiment

This article analyzes market sentiment for Evolus (EOLS) through key signals like analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with an average price target significantly above the current stock price, despite some recent downgrades …

Evolus Inc (EOLS) Income Statement

This article provides the quarterly and annual income statement for Evolus Inc (EOLS), detailing key financial metrics such as total revenue, cost of revenue, operating expenses, operating profit, and net income. It allows users to gain insights into the company's financial performance and operational …

Evolus Inc (EOLS) Cash Flow

This article provides a detailed historical cash flow statement for Evolus Inc (EOLS), covering annual and quarterly data across various financial metrics like operating, investing, and financing cash flows. It includes period-over-period changes and absolute values for numerous line items, allowing for an in-depth …

Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Evolus Inc (EOLS), listing major individual and institutional holders, their proportion of shares, and recent changes in their holdings. It also categorizes shareholders by type (e.g., Hedge Fund, Investment Advisor) and provides data on institutional shareholding trends …